Dimensional Fund Advisors LP Increases Stock Position in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)

Dimensional Fund Advisors LP boosted its holdings in shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Free Report) by 52.8% during the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 297,106 shares of the biotechnology company's stock after purchasing an additional 102,646 shares during the period. Dimensional Fund Advisors LP owned approximately 1.39% of Enanta Pharmaceuticals worth $1,708,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently modified their holdings of the company. AlphaQuest LLC lifted its holdings in shares of Enanta Pharmaceuticals by 16.4% in the 4th quarter. AlphaQuest LLC now owns 22,260 shares of the biotechnology company's stock valued at $128,000 after buying an additional 3,137 shares during the period. Invesco Ltd. lifted its holdings in shares of Enanta Pharmaceuticals by 7.3% during the 4th quarter. Invesco Ltd. now owns 46,614 shares of the biotechnology company's stock worth $268,000 after acquiring an additional 3,186 shares during the period. American Century Companies Inc. raised its position in shares of Enanta Pharmaceuticals by 10.5% in the 4th quarter. American Century Companies Inc. now owns 36,962 shares of the biotechnology company's stock worth $213,000 after buying an additional 3,501 shares during the period. China Universal Asset Management Co. Ltd. acquired a new position in shares of Enanta Pharmaceuticals in the 4th quarter valued at about $26,000. Finally, Wells Fargo & Company MN raised its stake in shares of Enanta Pharmaceuticals by 69.6% in the 4th quarter. Wells Fargo & Company MN now owns 15,881 shares of the biotechnology company's stock valued at $91,000 after acquiring an additional 6,518 shares during the period. 94.99% of the stock is currently owned by hedge funds and other institutional investors.

Enanta Pharmaceuticals Stock Down 1.0%

Shares of NASDAQ ENTA opened at $5.18 on Thursday. The business has a fifty day simple moving average of $5.55 and a 200-day simple moving average of $6.74. The company has a market cap of $110.50 million, a price-to-earnings ratio of -1.05 and a beta of 0.81. Enanta Pharmaceuticals, Inc. has a 12 month low of $4.09 and a 12 month high of $17.24.

Enanta Pharmaceuticals (NASDAQ:ENTA - Get Free Report) last posted its quarterly earnings results on Monday, May 12th. The biotechnology company reported ($1.06) earnings per share for the quarter, missing the consensus estimate of ($1.04) by ($0.02). The business had revenue of $14.93 million for the quarter, compared to analyst estimates of $15.96 million. Enanta Pharmaceuticals had a negative net margin of 157.57% and a negative return on equity of 75.53%. As a group, sell-side analysts expect that Enanta Pharmaceuticals, Inc. will post -4.65 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the stock. StockNews.com raised shares of Enanta Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Wednesday, February 19th. HC Wainwright restated a "buy" rating and set a $18.00 price objective on shares of Enanta Pharmaceuticals in a research note on Tuesday, February 11th. Finally, JMP Securities restated a "market outperform" rating and set a $21.00 price objective on shares of Enanta Pharmaceuticals in a research note on Tuesday, February 11th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, three have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Enanta Pharmaceuticals has a consensus rating of "Moderate Buy" and a consensus target price of $17.25.

Enanta Pharmaceuticals Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.